Table 1 Patient clinical characteristics in the PR group and SD_PD group with the treatment of camrelizumab plus gemcitabine and oxaliplatin (GEMOX)

From: Plasma proteomic biomarkers predict therapeutic responses in advanced biliary tract cancer patients receiving Camrelizumab plus the GEMOX treatment

Variable

Camrelizumab + GEMOX (N = 37)

P value

PR group (N = 21)

SD_PD group (N = 16)

Age

  

0.195

 <65

11 (52%)

11 (69%)

 

 ≥65

10 (48%)

5 (31%)

 

Sex

  

0.067

 Female

4 (19%)

7 (44%)

 

 Male

17 (81%)

9 (56%)

 

Set of origin

  

0.334

 Extrahepatic

3 (14%)

2 (13%)

 

 Gallbladder

10 (48%)

5 (31%)

 

 Intrahepatic

8 (38%)

9 (56%)

 

Surgery

  

0.080

 Yes

10 (48%)

11 (69%)

 

 No

11 (52%)

5 (31%)

 

PFS (months)

  

0.002

 Median

7.2

4.2

 

 Range

3.6 - 26.3

1.6–10.1

 

OS (months)

  

0.005

 Median

13.0

7.4

 

 Range

6.2 -27.9

4.6–22.1

 

PD-L1 expression

  

0.113

 Negative

15 (71%)

11 (69%)

 

 Positive

4 (19%)

1 (6%)

 

 Unknown

2 (10%)

4 (25%)

 
  1. PR partial response, SD stable disease, PD progressive disease, PFS progression-free survival, OS overall survival, PD-L1 programmed cell death ligand 1.
Back to article page